It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ependymoma is a tumor of the brain or spinal cord. The two most common and aggressive molecular groups of ependymoma are the supratentorial ZFTA-fusion associated and the posterior fossa ependymoma group A. In both groups, tumors occur mainly in young children and frequently recur after treatment. Although molecular mechanisms underlying these diseases have recently been uncovered, they remain difficult to target and innovative therapeutic approaches are urgently needed. Here, we use genome-wide chromosome conformation capture (Hi-C), complemented with CTCF and H3K27ac ChIP-seq, as well as gene expression and DNA methylation analysis in primary and relapsed ependymoma tumors, to identify chromosomal conformations and regulatory mechanisms associated with aberrant gene expression. In particular, we observe the formation of new topologically associating domains (‘neo-TADs’) caused by structural variants, group-specific 3D chromatin loops, and the replacement of CTCF insulators by DNA hyper-methylation. Through inhibition experiments, we validate that genes implicated by these 3D genome conformations are essential for the survival of patient-derived ependymoma models in a group-specific manner. Thus, this study extends our ability to reveal tumor-dependency genes by 3D genome conformations even in tumors that lack targetable genetic alterations.
Ependymoma is a tumor of the brain or spinal cord with the two most common and aggressive types mainly occurring in children. Here the authors employ 3D genomics and epigenomics to reveal targets for aggressive ependymoma tumors in children.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Pagadala, Meghana 3 ; Bump, Rosalind 6 ; Chandran, Sahaana 6 ; Kraft, Katerina 7 ; Acuna-Hidalgo, Rocio 8 ; Reid, Derek 9 ; Sikkink, Kristin 9
; Mauermann, Monika 1 ; Juarez, Edwin F. 3 ; Jenseit, Anne 10 ; Robinson, James T. 3 ; Pajtler, Kristian W. 11 ; Milde, Till 12
; Jäger, Natalie 1 ; Fiesel, Petra 13 ; Morgan, Ling 3 ; Sridhar, Sunita 3 ; Coufal, Nicole G. 14 ; Levy, Michael 15
; Malicki, Denise 16 ; Hobbs, Charlotte 17 ; Kingsmore, Stephen 17
; Nahas, Shareef 17 ; Snuderl, Matija 18 ; Crawford, John 19 ; Wechsler-Reya, Robert J. 20
; Davidson, Tom Belle 21
; Cotter, Jennifer 21
; Michaiel, George 21 ; Fleischhack, Gudrun 22
; Mundlos, Stefan 23
; Schmitt, Anthony 9 ; Carter, Hannah 3 ; Michealraj, Kulandaimanuvel Antony 24 ; Kumar, Sachin A. 24
; Taylor, Michael D. 24
; Rich, Jeremy 25 ; Buchholz, Frank 26
; Mesirov, Jill P. 27 ; Pfister, Stefan M. 11 ; Ay, Ferhat 28
; Dixon, Jesse R. 6
; Kool, Marcel 29 ; Chavez, Lukas 30
1 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
2 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), National Center for Tumor Diseases (NCT): German Cancer Research Center (DKFZ) Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
3 University of California San Diego (UCSD), Division of Genomics and Precision Medicine, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
4 University of California, San Diego, Division of Regenerative Medicine, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); 2880 Torrey Pines Scenic Drive, Sanford Consortium for Regenerative Medicine, La Jolla, USA (GRID:grid.468218.1) (ISNI:0000 0004 5913 3393)
5 La Jolla Institute for Immunology, Centers for Cancer Immunotherapy and Autoimmunity, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162)
6 Salk Institute for Biological Studies, Peptide Biology Labs, La Jolla, USA (GRID:grid.250671.7) (ISNI:0000 0001 0662 7144)
7 Stanford University, Center for Personal Dynamic Regulomes, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
8 Max Planck Institute for Molecular Genetics, Berlin, Germany (GRID:grid.419538.2) (ISNI:0000 0000 9071 0620); Charité Universitätsmedizin Berlin, Institute for Medical Genetics and Human Genetics, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
9 Arima Genomics, Inc, San Diego, USA (GRID:grid.504177.0)
10 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Heidelberg University, Faculty of Biosciences, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
11 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Heidelberg University Hospital, Department of Pediatric Oncology, Hematology and Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
12 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); Heidelberg University Hospital, Department of Pediatric Oncology, Hematology and Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), CCU Pediatric Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
13 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), CCU Neuropathology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
14 2880 Torrey Pines Scenic Drive, Sanford Consortium for Regenerative Medicine, La Jolla, USA (GRID:grid.468218.1) (ISNI:0000 0004 5913 3393); University of California, San Diego, Department of Pediatrics, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
15 University of California San Diego – Rady Children’s Hospital, Neurosurgery, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
16 University of California San Diego – Rady Children’s Hospital, Pathology, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
17 Rady Children’s Institute for Genomic Medicine, San Diego, USA (GRID:grid.286440.c) (ISNI:0000 0004 0383 2910)
18 NYU Grossman School of Medicine, Department of Pathology, NYU Langone Health, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); NYU Langone Health, Laura and Isaac Perlmutter Cancer Center, New York, USA (GRID:grid.240324.3) (ISNI:0000 0001 2109 4251)
19 University of California San Diego – Rady Children’s Hospital, Department of Neurosciences, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
20 2880 Torrey Pines Scenic Drive, Sanford Consortium for Regenerative Medicine, La Jolla, USA (GRID:grid.468218.1) (ISNI:0000 0004 5913 3393); University of California, San Diego, Department of Pediatrics, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Sanford Burnham Prebys Medical Discovery Institute, Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573)
21 Children’s Hospital Los Angeles, Division of Hematology-Oncology, Cancer and Blood Disease Institute and Department of Pediatrics, Los Angeles, USA (GRID:grid.239546.f) (ISNI:0000 0001 2153 6013)
22 University Hospital Essen, German Cancer Consortium (DKTK), West German Cancer Center, Pediatrics III, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331)
23 Max Planck Institute for Molecular Genetics, Berlin, Germany (GRID:grid.419538.2) (ISNI:0000 0000 9071 0620)
24 University of Toronto, Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
25 University of California, San Diego, Division of Regenerative Medicine, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); 2880 Torrey Pines Scenic Drive, Sanford Consortium for Regenerative Medicine, La Jolla, USA (GRID:grid.468218.1) (ISNI:0000 0004 5913 3393); University of California San Diego, Department of Neurosciences, School of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
26 Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), National Center for Tumor Diseases (NCT): German Cancer Research Center (DKFZ) Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Medical Systems Biology, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Heidelberg and German Cancer Consortium (DKTK) Partner Site Dresden, German Cancer Research Center (DKFZ), Dresden, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
27 University of California San Diego (UCSD), Division of Genomics and Precision Medicine, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California San Diego (UCSD), Moores Cancer Center, La Jolla, USA (GRID:grid.516081.b) (ISNI:0000 0000 9217 9714)
28 La Jolla Institute for Immunology, Centers for Cancer Immunotherapy and Autoimmunity, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162); University of California, San Diego, Department of Pediatrics, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
29 Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands (GRID:grid.487647.e)
30 University of California San Diego (UCSD), Division of Genomics and Precision Medicine, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Rady Children’s Institute for Genomic Medicine, San Diego, USA (GRID:grid.286440.c) (ISNI:0000 0004 0383 2910); Sanford Burnham Prebys Medical Discovery Institute, Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573); University of California San Diego (UCSD), Moores Cancer Center, La Jolla, USA (GRID:grid.516081.b) (ISNI:0000 0000 9217 9714)




